Sight Sciences, Inc.

NasdaqGS SGHT

Sight Sciences, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD -25.89 M

Sight Sciences, Inc. Free Cash Flow is USD -25.89 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 54.47% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Sight Sciences, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -56.86 M, a 21.23% change year over year.
Sight Sciences, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -72.18 M, a -40.64% change year over year.
Sight Sciences, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -51.33 M.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

NasdaqGS: SGHT

Sight Sciences, Inc.

CEO	Mr. Paul Badawi
IPO Date	July 15, 2021
Location	United States
Headquarters	4040 Campbell Avenue
Employees	214
Sector	Consumer Discretionary
Industries Eyewear Medical Instruments Pharmaceuticals

Description

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.

Key trends

Past 5 years